• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

持续性非卧床腹膜透析患者缺血性心脏病的危险因素

Risk factors of ischemic cardiac disease in patients on continuous ambulatory peritoneal dialysis.

作者信息

Cavagna R, Schiavon R, Tessarin C, Papa N, Scorrano D, Casol D, De Silvestro L

机构信息

Nephrology and Dialysis Unit, City Hospital of Belluno, Italy.

出版信息

Perit Dial Int. 1993;13 Suppl 2:S402-5.

PMID:8399623
Abstract

Elevated plasma levels of fibrinogen, factor VII coagulant activity (F VIIc), and plasminogen activator inhibitor (PAI-1) have been reported to be strictly associated with thrombotic events and are considered to be important risk markers of atherothrombotic cardiovascular disease. Therefore, we evaluated in 15 patients on continuous ambulatory peritoneal dialysis (CAPD) the plasma levels of these coagulation factors, basal insulin values, and the lipid pattern in comparison with 33 hemodialysis (HD) patients and 59 healthy subjects. In CAPD the total cholesterol and triglyceride results were significantly increased, but no difference was found in HDL cholesterol. Fibrinogen and F VIIc results were significantly higher in CAPD and HD than in the control group, probably due to an increased hepatic synthesis as a nonspecific response to the peritoneal protein loss. Elevated F VIIc activity may be caused by the presence of large negatively charged lipoproteins, in vivo thrombin formation, or reduced hepatic clearance. Both PAI 1 and t-PA results were higher in CAPD, probably due to an increased synthesis by endothelial cells activated by glucose peritoneal absorption and hypertonic dialysis solutions. The contemporary elevation of fibrinogen, F VIIc, PAI-1, and t-PA suggests that CAPD patients present a hypercoagulability and hypofibrinolysis condition, which may promote the development of atherothrombotic events.

摘要

据报道,血浆纤维蛋白原、凝血因子VII促凝活性(F VIIc)和纤溶酶原激活物抑制剂(PAI - 1)水平升高与血栓形成事件密切相关,被认为是动脉粥样硬化性心血管疾病的重要风险标志物。因此,我们对15例持续非卧床腹膜透析(CAPD)患者的这些凝血因子血浆水平、基础胰岛素值和血脂模式进行了评估,并与33例血液透析(HD)患者和59例健康受试者进行了比较。在CAPD患者中,总胆固醇和甘油三酯结果显著升高,但高密度脂蛋白胆固醇未见差异。CAPD和HD患者的纤维蛋白原和F VIIc结果显著高于对照组,这可能是由于肝脏合成增加,作为对腹膜蛋白丢失的非特异性反应。F VIIc活性升高可能是由于存在大量带负电荷的脂蛋白、体内凝血酶形成或肝脏清除率降低。CAPD患者的PAI - 1和组织型纤溶酶原激活物(t - PA)结果均较高,这可能是由于葡萄糖腹膜吸收和高渗透析液激活内皮细胞后合成增加所致。纤维蛋白原、F VIIc、PAI - 1和t - PA同时升高表明CAPD患者存在高凝状态和纤溶功能低下,这可能促进动脉粥样硬化血栓形成事件的发生。

相似文献

1
Risk factors of ischemic cardiac disease in patients on continuous ambulatory peritoneal dialysis.持续性非卧床腹膜透析患者缺血性心脏病的危险因素
Perit Dial Int. 1993;13 Suppl 2:S402-5.
2
Fibrinogen, coagulation factor VII, tissue plasminogen activator, plasminogen activator inhibitor-1, and lipid as cardiovascular risk factors in chronic hemodialysis and continuous ambulatory peritoneal dialysis patients.纤维蛋白原、凝血因子VII、组织型纤溶酶原激活剂、纤溶酶原激活剂抑制剂-1以及脂质作为慢性血液透析和持续性非卧床腹膜透析患者的心血管危险因素。
Am J Kidney Dis. 1996 Jun;27(6):848-54. doi: 10.1016/s0272-6386(96)90523-5.
3
Increased plasma lipoprotein(a) in continuous ambulatory peritoneal dialysis is related to peritoneal transport of proteins and glucose.持续非卧床腹膜透析患者血浆脂蛋白(a)升高与蛋白质和葡萄糖的腹膜转运有关。
Nephron. 1996;72(2):135-44. doi: 10.1159/000188831.
4
Comparison of hemostatic disturbances between patients on CAPD and patients on hemodialysis.
Perit Dial Int. 2001 Mar-Apr;21(2):158-65.
5
Fibrinogen and fibrinolytic activity in CAPD patients with atherosclerosis and its correlation with serum albumin.伴有动脉粥样硬化的持续性非卧床腹膜透析患者的纤维蛋白原和纤溶活性及其与血清白蛋白的相关性
Perit Dial Int. 1997 Mar-Apr;17(2):157-61.
6
The determination of insulin sensitivity in hemodialysis and continuous ambulatory peritoneal dialysis in nondiabetic patients with end-stage renal disease.非糖尿病终末期肾病患者血液透析和持续性非卧床腹膜透析时胰岛素敏感性的测定
Saudi Med J. 2005 May;26(5):786-91.
7
Plasminogen activator inhibitor-1 activity in chronic renal disease and dialysis.慢性肾病及透析中的纤溶酶原激活物抑制剂-1活性
Metabolism. 1997 Jan;46(1):36-40. doi: 10.1016/s0026-0495(97)90164-5.
8
Cardiovascular risk factors in diabetic patients undergoing continuous ambulatory peritoneal dialysis.接受持续性非卧床腹膜透析的糖尿病患者的心血管危险因素
Adv Perit Dial. 1996;12:120-5.
9
Lipid parameters including lipoprotein (a) in patients undergoing CAPD and hemodialysis.接受持续性非卧床腹膜透析和血液透析患者的血脂参数,包括脂蛋白(a) 。
Perit Dial Int. 1995 Oct-Dec;15(8):342-7.
10
Tissue plasminogen activator (t-PA) and plasminogen activator inhibitor-I (PAI-I) levels in plasma and peritoneal effluent in patients on CAPD.持续性非卧床腹膜透析(CAPD)患者血浆及腹膜透析液中组织型纤溶酶原激活物(t-PA)和纤溶酶原激活物抑制剂-I(PAI-I)水平
Adv Perit Dial. 1992;8:160-5.